JPRN-jRCT2080222404未知3 期
A phase III, multicenter, open-label study to evaluate the safety and immunogenicity of intramuscular TAK-816 in healthy infants
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 30 人开始时间: 2014年2月21日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Healthy Japanese infants
- •2.Male or female infants aged 2-6 months (>=2 and <7 months) at the time of the first dose of investigational product (excluding hospitalized infants)
- •3.Infants whose parents or legal guardians have agreed to cooperate with the investigator during the study period.
排除标准
- •1. Any serious acute illness.
- •2. Any underlying cardiovascular, renal, hepatic, or hematologic disease, and/or developmental disorder.
- •3. History of possible Haemophilus influenzae type b (Hib) infection.
- •4. Previously diagnosed immunodeficiency.
- •5. Documented history of anaphylaxis to any ingredients of the investigational product (e.g., diphtheria toxoid)
- •6. A history of convulsions.
- •7. Previous administration of another Hib vaccine.
- •8. Treatment with any live vaccine during the 27 days before the first dose of TAK-816 or with any inactivated vaccine during the 6 days before dosing.
- •9. Prior participation in any clinical study or post-marketing clinical study
- •10. Previously receipt of blood transfusions, gamma globulin preparations (except monoclonal vaccines as antigens), systemic immunosuppressive therapy, or systemic corticosteroids, or a plan to receive any of these products during the study period
- •11. Presence of thrombocytopenia or coagulopathy
研究者
相似试验
进行中（未招募）
3 期
A Phase III study to evaluate the efficacy and safety of NRL-1 intranasally administered in Japanese pediatric patients with status epilepticusJPRN-jRCT2031220265akagawa Eiji15
进行中（未招募）
3 期
A large, multi-clinic study to evaluate contraceptive efficacy and safety of depot medroxyprogesterone acetate (150 mg/ml) injected under the skin every 6 monthsContraception for up to 6 monthsPregnancy and ChildbirthISRCTN62695528Family Health International 360750
进行中（未招募）
1 期
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals? influenza vaccine when administered in children who previously participated in study 115345Healthy volunteers (Immunization against influenza A and B in children aged 18 to 47 months)MedDRA version: 14.1Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-001230-34-ESGlaxoSmithKline S.A.470
进行中（未招募）
1 期
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ influenza vaccine when administered in children who previously participated in study 115345EUCTR2012-001230-34-PLGlaxoSmithKline Biologicals452
进行中（未招募）
不适用
Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ influenza vaccine when administered in children who previously participated in study 115345Healthy volunteers (Immunization against influenza A and B in children aged 18 to 47 months)MedDRA version: 14.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-001230-34-CZGlaxoSmithKline Biologicals452